Relay Therapeutics Moves to Buy Rationale Behind the Upgrade
| RLAY Stock | USD 4.16 0.10 2.35% |
Slightly above 68% of Relay Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Relay Therapeutics suggests that many traders are alarmed. Relay Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Relay Therapeutics' earnings reports, geopolitical events, and overall market trends.
Relay |
Relay Therapeutics has been upgraded to a Zacks Rank 2 , reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Read at zacks.com
 |
Relay Therapeutics Fundamental Analysis
We analyze Relay Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relay Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relay Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Relay Therapeutics is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Relay Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Relay Therapeutics stock to make a market-neutral strategy. Peer analysis of Relay Therapeutics could also be used in its relative valuation, which is a method of valuing Relay Therapeutics by comparing valuation metrics with similar companies.
Peers
Relay Therapeutics Related Equities
| GLUE | Monte Rosa | 6.45 | ||||
| CGEM | Cullinan Oncology | 5.94 | ||||
| IPSC | Century Therapeutics | 4.76 | ||||
| MLYS | Mineralys Therapeutics, | 4.31 | ||||
| ARVN | Arvinas | 3.65 | ||||
| STOK | Stoke Therapeutics | 3.36 | ||||
| DAWN | Day One | 2.65 | ||||
| CCCC | C4 Therapeutics | 2.60 | ||||
| AMLX | Amylyx Pharmaceuticals | 2.27 | ||||
| FHTX | Foghorn Therapeutics | 1.43 | ||||
| BDTX | Black Diamond | 1.37 | ||||
| BPMC | Blueprint Medicines | 1.36 | ||||
| APLS | Apellis Pharmaceuticals | 0.21 | ||||
| EWTX | Edgewise Therapeutics | 0.06 | ||||
| PLRX | Pliant Therapeutics | 0.68 | ||||
| NRIX | Nurix Therapeutics | 1.05 | ||||
| TERN | Terns Pharmaceuticals | 3.14 |
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.